# Capricor Therapeutics, Inc.: financial statements, quarterly

CAPR · Nasdaq · CIK 1133869 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/capr.md) · [Financials](/companies/capr/financials.md) · [Filings](/companies/capr/filings.md) · [Insiders](/companies/capr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/capr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [6.2](/filings/0001558370-24-015730.md) | [12.1 d](/filings/0001558370-25-003707.md) | [4.9](/filings/0001558370-25-007770.md) | [4.0](/filings/0001558370-25-011084.md) | [2.3](/filings/0001104659-25-109298.md) | [11.1 d](/filings/0001104659-26-029580.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [10.0](/filings/0001558370-24-015730.md) | [9.9 d](/filings/0001558370-25-003707.md) | [11.1](/filings/0001558370-25-007770.md) | [12.5](/filings/0001558370-25-011084.md) | [11.8](/filings/0001104659-25-109298.md) | [14.6 d](/filings/0001104659-26-029580.md) | [18.9](/filings/0001104659-26-060382.md) | [22.0](/filings/0001104659-26-097294.md) | [20.4](/filings/0001104659-25-109298.md) | [23.1 d](/filings/0001104659-26-029580.md) | [27.4](/filings/0001104659-26-060382.md) | [28.9](/filings/0001104659-26-097294.md) |
| Operating income | $m | [(6.9)](/filings/0001558370-24-015730.md) | [(1.3) d](/filings/0001558370-25-003707.md) | [(10.3)](/filings/0001558370-25-007770.md) | [(11.6)](/filings/0001558370-25-011084.md) | [(13.0)](/filings/0001104659-25-109298.md) | [(7.7) d](/filings/0001104659-26-029580.md) | [(25.0)](/filings/0001104659-26-060382.md) | [(27.7)](/filings/0001104659-26-097294.md) | [(26.3)](/filings/0001104659-25-109298.md) | [(29.2) d](/filings/0001104659-26-029580.md) | [(36.8)](/filings/0001104659-26-060382.md) | [(42.9)](/filings/0001104659-26-097294.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001104659-26-060382.md) | [0.0](/filings/0001104659-26-097294.md) | not reported | not reported | [0.0](/filings/0001104659-26-060382.md) | [0.0](/filings/0001104659-26-097294.md) |
| Net income | $m | [(6.4)](/filings/0001558370-24-015730.md) | [(0.8) d](/filings/0001558370-25-003707.md) | [(9.8)](/filings/0001104659-25-109298.md) | [(11.0)](/filings/0001104659-25-109298.md) | [(12.6)](/filings/0001104659-25-109298.md) | [(7.1) d](/filings/0001104659-26-029580.md) | [(24.4)](/filings/0001104659-26-097294.md) | [(25.9)](/filings/0001104659-26-097294.md) | [(24.6)](/filings/0001104659-25-109298.md) | [(30.2) d](/filings/0001104659-26-029580.md) | [(33.9)](/filings/0001104659-26-097294.md) | [(40.7)](/filings/0001104659-26-097294.md) |
| Diluted EPS | $ per share | [(0.25)](/filings/0001558370-24-015730.md) | not reported | [(0.31)](/filings/0001558370-25-007770.md) | [(0.35)](/filings/0001558370-25-011084.md) | [(0.38)](/filings/0001104659-25-109298.md) | not reported | [(0.53)](/filings/0001104659-26-060382.md) | [(0.57)](/filings/0001104659-26-097294.md) | [(0.54)](/filings/0001104659-25-109298.md) | not reported | [(0.59)](/filings/0001104659-26-060382.md) | [(0.70)](/filings/0001104659-26-097294.md) |
| Basic EPS | $ per share | [(0.25)](/filings/0001558370-24-015730.md) | not reported | [(0.31)](/filings/0001558370-25-007770.md) | [(0.35)](/filings/0001558370-25-011084.md) | [(0.38)](/filings/0001104659-25-109298.md) | not reported | [(0.53)](/filings/0001104659-26-060382.md) | [(0.57)](/filings/0001104659-26-097294.md) | [(0.54)](/filings/0001104659-25-109298.md) | not reported | [(0.59)](/filings/0001104659-26-060382.md) | [(0.70)](/filings/0001104659-26-097294.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [9.0](/filings/0001558370-23-019065.md) | [14.7](/filings/0001558370-25-003707.md) | [6.2](/filings/0001558370-24-008072.md) | [10.7](/filings/0001558370-24-011638.md) | [68.4](/filings/0001558370-24-015730.md) | [11.3](/filings/0001104659-26-029580.md) | [28.8](/filings/0001558370-25-007770.md) | [23.2](/filings/0001558370-25-011084.md) | [19.5](/filings/0001104659-25-109298.md) | [288](/filings/0001104659-26-097294.md) | [105](/filings/0001104659-26-060382.md) | [20.9](/filings/0001104659-26-097294.md) |
| Current assets | $m | [29.5](/filings/0001558370-23-019065.md) | [50.9](/filings/0001558370-25-003707.md) | [41.4](/filings/0001558370-24-008072.md) | [30.7](/filings/0001558370-24-011638.md) | [85.8](/filings/0001558370-24-015730.md) | [163](/filings/0001104659-26-029580.md) | [146](/filings/0001558370-25-007770.md) | [124](/filings/0001558370-25-011084.md) | [101](/filings/0001104659-25-109298.md) | [323](/filings/0001104659-26-097294.md) | [283](/filings/0001104659-26-060382.md) | [242](/filings/0001104659-26-097294.md) |
| Total assets | $m | [37.2](/filings/0001558370-23-019065.md) | [58.7](/filings/0001558370-25-003707.md) | [49.4](/filings/0001558370-24-008072.md) | [38.3](/filings/0001558370-24-011638.md) | [93.0](/filings/0001558370-24-015730.md) | [170](/filings/0001104659-26-029580.md) | [154](/filings/0001558370-25-007770.md) | [134](/filings/0001558370-25-011084.md) | [126](/filings/0001104659-25-109298.md) | [356](/filings/0001104659-26-097294.md) | [326](/filings/0001104659-26-060382.md) | [369](/filings/0001104659-26-097294.md) |
| Current liabilities | $m | [32.9](/filings/0001558370-23-019065.md) | [31.3](/filings/0001558370-25-003707.md) | [26.4](/filings/0001558370-24-008072.md) | [22.4](/filings/0001558370-24-011638.md) | [20.5](/filings/0001558370-24-015730.md) | [21.0](/filings/0001104659-26-029580.md) | [22.3](/filings/0001558370-25-007770.md) | [28.4](/filings/0001558370-25-011084.md) | [28.1](/filings/0001104659-25-109298.md) | [35.8](/filings/0001104659-26-097294.md) | [33.6](/filings/0001104659-26-060382.md) | [33.0](/filings/0001104659-26-097294.md) |
| Total liabilities | $m | [38.9](/filings/0001558370-23-019065.md) | [36.1](/filings/0001558370-25-003707.md) | [31.0](/filings/0001558370-24-008072.md) | [26.8](/filings/0001558370-24-011638.md) | [24.7](/filings/0001558370-24-015730.md) | [25.0](/filings/0001104659-26-029580.md) | [26.1](/filings/0001558370-25-007770.md) | [28.6](/filings/0001558370-25-011084.md) | [42.6](/filings/0001104659-25-109298.md) | [50.2](/filings/0001104659-26-097294.md) | [47.6](/filings/0001104659-26-060382.md) | [123](/filings/0001104659-26-097294.md) |
| Shareholders' equity | $m | [(1.8)](/filings/0001558370-24-015730.md) | [22.6](/filings/0001104659-26-029580.md) | [18.4](/filings/0001104659-25-109298.md) | [11.5](/filings/0001104659-25-109298.md) | [68.3](/filings/0001104659-25-109298.md) | [145](/filings/0001104659-26-097294.md) | [128](/filings/0001104659-26-097294.md) | [105](/filings/0001104659-26-097294.md) | [83.9](/filings/0001104659-25-109298.md) | [306](/filings/0001104659-26-097294.md) | [279](/filings/0001104659-26-097294.md) | [246](/filings/0001104659-26-097294.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(8.8) d](/filings/0001558370-24-015730.md) | [(11.6) d](/filings/0001558370-25-003707.md) | [(1.3)](/filings/0001558370-25-007770.md) | [(12.3) d](/filings/0001558370-25-011084.md) | [(11.6) d](/filings/0001104659-25-109298.md) | [(14.8) d](/filings/0001104659-26-029580.md) | [(6.4)](/filings/0001104659-26-060382.md) | [(20.1) d](/filings/0001104659-26-097294.md) | [(19.7) d](/filings/0001104659-25-109298.md) | [(23.6) d](/filings/0001104659-26-029580.md) | [(29.3)](/filings/0001104659-26-060382.md) | [(31.5) d](/filings/0001104659-26-097294.md) |
| Capital expenditure | $m | [0.3 d](/filings/0001558370-24-015730.md) | [0.6 d](/filings/0001558370-25-003707.md) | [0.6](/filings/0001558370-25-007770.md) | [0.1 d](/filings/0001558370-25-011084.md) | [0.0 d](/filings/0001104659-25-109298.md) | [0.5 d](/filings/0001104659-26-029580.md) | [0.9](/filings/0001104659-26-060382.md) | [0.3 d](/filings/0001104659-26-097294.md) | [0.1 d](/filings/0001104659-25-109298.md) | [1.7 d](/filings/0001104659-26-029580.md) | [5.1](/filings/0001104659-26-060382.md) | [4.1 d](/filings/0001104659-26-097294.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [24.4](/filings/0001558370-23-019065.md) | [25.2](/filings/0001558370-24-008072.md) | [25.3](/filings/0001558370-24-011638.md) | [25.8](/filings/0001558370-24-015730.md) | [31.4](/filings/0001558370-25-007770.md) | [31.8](/filings/0001558370-25-011084.md) | [33.1](/filings/0001104659-25-109298.md) | [45.6](/filings/0001104659-26-060382.md) | [45.7](/filings/0001104659-26-097294.md) | [45.7](/filings/0001104659-25-109298.md) | [57.4](/filings/0001104659-26-060382.md) | [57.9](/filings/0001104659-26-097294.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 58,138,989 at 2026-08-13, from the cover of the [10-Q filed 2026-08-14](/filings/0001104659-26-097294.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.